Welcome to the Ludwig Institute for Cancer Research Oxford Branch

The Ludwig Institute for Cancer Research Ltd (LICR) is a global non-profit organisation committed to improving the understanding and control of cancer though integrated laboratory and clinical discovery.

Founded in 1971 by the American businessman Daniel K. Ludwig, LICR now has nine Branches in seven countries across Australasia, Europe, and North and South America, and numerous affiliates in many other countries. LICR engages leading scientists and clinicians in an integrated effort to understand and confront the global challenge of cancer. It brings together recognized leaders in many areas of science and oncology, and is one of twenty international organizations recognized as producing research articles of extremely high impact.

The Ludwig Institute for Cancer Research Oxford Branch aims to develop novel and successful strategies to suppress tumour growth and metastasis. Research within the branch currently utilises melanoma and lung tumours as model systems to identify new molecular targets, biomarkers and therapeutic strategies. In particular, the branch focuses on molecular pathways that affect cancer susceptibility, cellular senescence, apoptosis and the differentiation of stem cells to a defined cell lineage.